Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 19/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | NT5E | P21589 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dihydrobetulonic Acid SCHEMBL3276418 | 1.00 | GPBAR1 (0.71) | GPBAR1LMNANT5ESMN1; SMN2PRKCD | |
| Dihydrobetulonic Acid SCHEMBL10061167 | 1.00 | GPBAR1 (0.71) | GPBAR1LMNANT5ESMN1; SMN2PRKCD | |
| Dihydrobetulonic Acid SCHEMBL14414141 | 1.00 | GPBAR1 (0.71) | GPBAR1LMNANT5ESMN1; SMN2PRKCD | |
| SCHEMBL10061168 | 0.91 | GPBAR1 (0.59) | GPBAR1LMNANT5ESMN1; SMN2PRKCD | |
| SCHEMBL16511700 | 0.91 | GPBAR1 (0.59) | GPBAR1LMNANT5ESMN1; SMN2PRKCD | |
| SCHEMBL13956965 | 0.90 | GPBAR1 (0.69) | GPBAR1LMNANT5ESMN1; SMN2PRKCD | |
| Methyl Dihydrobetulonate SCHEMBL13747683 | 0.89 | GPBAR1 (0.58) | GPBAR1LMNANT5ESMN1; SMN2PRKCD | |
| SCHEMBL13301977 | 0.89 | GPBAR1 (0.65) | GPBAR1LMNANT5ESMN1; SMN2PRKCD | |
| SCHEMBL9891261 | 0.89 | GPBAR1 (0.57) | GPBAR1LMNANT5ESMN1; SMN2PRKCD | |
| SCHEMBL14134447 | 0.89 | GPBAR1 (0.65) | GPBAR1LMNANT5ESMN1; SMN2PRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8586569-B2 | Betulonic and betulinic acid derivatives | Leunis, Jean-Claude (BE) | 2013-11-19 | — | — | US | disclosed |
| US-20090068257-A1 | BETULONIC AND BETULINIC ACID DERIVATIVES | JEAN-CLAUDE LEUNIS (BE) | 2009-03-12 | — | — | US | disclosed |
| US-20090068257-A1 | BETULONIC AND BETULINIC ACID DERIVATIVES | JEAN-CLAUDE LEUNIS (BE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090068257-A1 | BETULONIC AND BETULINIC ACID DERIVATIVES | BET1, PGGT1B, PAG1 | GPBAR1 100/4885LMNA 3136/4885NT5E 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.